Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis

A Watanabe, M Iwagami, J Yasuhara, H Takagi, T Kuno - Vaccine, 2023 - Elsevier
Background The relationship between coronavirus disease 2019 (COVID-19) vaccination
and long COVID has not been firmly established. We conducted a systematic review and …

[HTML][HTML] Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis

C Zheng, W Shao, X Chen, B Zhang, G Wang… - International journal of …, 2022 - Elsevier
Objective To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE)
against concerned outcomes in real-world settings. Methods Studies reporting COVID-19 VE …

Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19

MJ Levin, A Ustianowski, S De Wit… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study

D Ayoubkhani, C Bermingham, KB Pouwels… - bmj, 2022 - bmj.com
Objective To estimate associations between covid-19 vaccination and long covid symptoms
in adults with SARS-CoV-2 infection before vaccination. Design Observational cohort study …

Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England

N Andrews, J Stowe, F Kirsebom, S Toffa… - Nature medicine, 2022 - nature.com
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in
England starting on 14 September 2021. We used a test-negative case–control design to …

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

SY Tartof, JM Slezak, H Fischer, V Hong, BK Ackerson… - The Lancet, 2021 - thelancet.com
Background Vaccine effectiveness studies have not differentiated the effect of the delta (B.
1.617. 2) variant and potential waning immunity in observed reductions in effectiveness …

Effect of Covid-19 vaccination on transmission of alpha and delta variants

DW Eyre, D Taylor, M Purver, D Chapman… - … England Journal of …, 2022 - Mass Medical Soc
Background Before the emergence of the B. 1.617. 2 (delta) variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination reduced transmission of …

Duration of protection against mild and severe disease by Covid-19 vaccines

N Andrews, E Tessier, J Stowe, C Gower… - … England Journal of …, 2022 - Mass Medical Soc
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …

Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination

P Irrgang, J Gerling, K Kocher, D Lapuente… - Science …, 2022 - science.org
RNA vaccines are efficient preventive measures to combat the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) pandemic. High levels of neutralizing SARS-CoV-2 …

[HTML][HTML] Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based …

M Antonelli, RS Penfold, J Merino… - The Lancet Infectious …, 2022 - thelancet.com
Background COVID-19 vaccines show excellent efficacy in clinical trials and effectiveness in
real-world data, but some people still become infected with SARS-CoV-2 after vaccination …